Development of resistance towards conventional antibiotics has become a huge problem worldwide. Infections which used to be easily treatable are now difficult to treat due to development of resistance. Therefore, we must turn to other approaches such as use of helper compounds. Helper compounds usually have no antibacterial properties themselves, however, when combined with antibiotics they are able to potentiate the effect of the antibiotic.
In our group, we are searching for novel helper compounds to be used in combination with antibiotics to fight resistant bacteria.
A potential helper compound is the cannabinoid cannabidiol (CBD) (Patent No. 17176612.4 - 1466). In our study, we have found through growth experiments that it is able to potentiate the effect of bacitracin against Methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria such as Listeria monocytogenes and Enterococcus faecalis.
Currently, we are working to clarify the mechanism of action of CBD and how it potentiates the effect of bacitracin. Therefore, various molecular experiments have been conducted such as RNA-sequencing of treated bacteria and whole-genome sequencing of CBD resistant strains. These results have led to several interesting genes selected for further studies. In addition, treatment with CBD have also shown to disrupt the membrane potential leading us to look further into how CBD affects the bacterial membrane. Therefore, we are currently looking on how CBD affects membrane fatty acid composition, fluidity and surface charge.
In conclusion, CBD is able to potentiate the effect of bacitracin towards MRSA, however, the mechanism of action still remains unknown.
|Konference||18th International Symposium on Staphylococci and Staphylococcal infections|
|Lokation||Mærsk Tower, Panuminstituttet|
|Periode||23/08/2018 → 26/08/2018|